Vyne Therapeutics Inc (VYNE) has a current Price-to-Book (P/B) ratio of 0.57. Compared to its 3-year average P/B ratio of 0.53, the current P/B ratio is approximately 9.02% higher. Relative to its 5-year average P/B ratio of 0.83, the current P/B ratio is about -30.85% higher. Vyne Therapeutics Inc (VYNE) has a Forward Free Cash Flow (FCF) yield of approximately -199.33%. Compared to its 3-year average FCF yield of -175.04%, the current FCF yield is approximately 13.88% lower. Relative to its 5-year average FCF yield of -168.37%, the current FCF yield is about 18.39% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for VYNE competitors is 44.81, providing a benchmark for relative valuation. Vyne Therapeutics Inc Corp (VYNE.O) exhibits a P/S ratio of 24.91, which is -44.41% above the industry average. Given its robust revenue growth of 54.76%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of VYNE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of VYNE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is VYNE currently overvalued or undervalued?

What is Vyne Therapeutics Inc (VYNE) fair value?

VYNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Vyne Therapeutics Inc (VYNE) is between 0.46 to 2.31 according to relative valuation method.

How does VYNE's valuation metrics compare to the industry average?

The average P/S ratio for VYNE's competitors is 44.81, providing a benchmark for relative valuation. Vyne Therapeutics Inc Corp (VYNE) exhibits a P/S ratio of 24.91, which is -44.41% above the industry average. Given its robust revenue growth of 54.76%, this premium appears sustainable.

What is the current P/B ratio for Vyne Therapeutics Inc (VYNE) as of Mar 02 2026?

As of Mar 02 2026, Vyne Therapeutics Inc (VYNE) has a P/B ratio of 0.57. This indicates that the market values VYNE at 0.57 times its book value.

What is the current FCF Yield for Vyne Therapeutics Inc (VYNE) as of Mar 02 2026?

As of Mar 02 2026, Vyne Therapeutics Inc (VYNE) has a FCF Yield of -199.33%. This means that for every dollar of Vyne Therapeutics Inc's market capitalization, the company generates -199.33 cents in free cash flow.

What is the current Forward P/E ratio for Vyne Therapeutics Inc (VYNE) as of Mar 02 2026?

As of Mar 02 2026, Vyne Therapeutics Inc (VYNE) has a Forward P/E ratio of -0.75. This means the market is willing to pay $-0.75 for every dollar of Vyne Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Vyne Therapeutics Inc (VYNE) as of Mar 02 2026?

As of Mar 02 2026, Vyne Therapeutics Inc (VYNE) has a Forward P/S ratio of 24.91. This means the market is valuing VYNE at $24.91 for every dollar of expected revenue over the next 12 months.

VYNE Valuation